Galmed Pharmaceuticals (GLMD) Competitors $1.38 +0.02 (+1.47%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.38 +0.00 (+0.29%) As of 04/17/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLMD vs. GELS, NXTC, TSBX, APRE, CARM, ACXP, KPRX, CHRO, PMCB, and OBSVShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Gelteq (GELS), NextCure (NXTC), Turnstone Biologics (TSBX), Aprea Therapeutics (APRE), Carisma Therapeutics (CARM), Acurx Pharmaceuticals (ACXP), Kiora Pharmaceuticals (KPRX), Chromocell Therapeutics (CHRO), PharmaCyte Biotech (PMCB), and ObsEva (OBSV). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. Gelteq NextCure Turnstone Biologics Aprea Therapeutics Carisma Therapeutics Acurx Pharmaceuticals Kiora Pharmaceuticals Chromocell Therapeutics PharmaCyte Biotech ObsEva Galmed Pharmaceuticals (NASDAQ:GLMD) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation. Do institutionals and insiders hold more shares of GLMD or GELS? 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better valuation & earnings, GLMD or GELS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalmed PharmaceuticalsN/AN/A-$6.91M-$16.66-0.08GelteqN/AN/AN/AN/AN/A Does the MarketBeat Community prefer GLMD or GELS? Galmed Pharmaceuticals received 442 more outperform votes than Gelteq when rated by MarketBeat users. CompanyUnderperformOutperformGalmed PharmaceuticalsOutperform Votes44262.70% Underperform Votes26337.30% GelteqN/AN/A Do analysts recommend GLMD or GELS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GLMD or GELS more profitable? Gelteq's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Galmed PharmaceuticalsN/A -28.75% -24.98% Gelteq N/A N/A N/A Does the media refer more to GLMD or GELS? In the previous week, Galmed Pharmaceuticals had 4 more articles in the media than Gelteq. MarketBeat recorded 6 mentions for Galmed Pharmaceuticals and 2 mentions for Gelteq. Gelteq's average media sentiment score of 0.37 beat Galmed Pharmaceuticals' score of 0.24 indicating that Gelteq is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gelteq 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryGalmed Pharmaceuticals beats Gelteq on 5 of the 8 factors compared between the two stocks. Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.28M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.086.8921.8017.78Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.045.916.443.97Net Income-$6.91M$142.72M$3.21B$247.65M7 Day Performance4.55%4.38%2.85%1.80%1 Month Performance-45.02%-12.76%-8.64%-6.98%1 Year Performance-69.51%-9.69%11.38%1.34% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals1.0874 of 5 stars$1.38+1.5%N/A-67.8%$2.28MN/A-0.0820Short Interest ↑News CoverageGELSGelteqN/A$0.93+13.4%N/AN/A$8.78MN/A0.00N/ANews CoverageGap UpNXTCNextCure4.202 of 5 stars$0.31+7.2%$3.50+1,021.8%-76.1%$8.74MN/A-0.1590High Trading VolumeTSBXTurnstone Biologics2.58 of 5 stars$0.38-2.1%$0.45+19.4%-87.7%$8.72M$19.31M-0.1282Gap DownAPREAprea Therapeutics2.55 of 5 stars$1.58+1.9%$15.50+881.0%-73.8%$8.68M$580,000.00-0.567Gap DownCARMCarisma Therapeutics2.2315 of 5 stars$0.21+3.0%$1.93+802.5%-88.6%$8.65M$19.63M-0.1420Positive NewsACXPAcurx Pharmaceuticals2.1244 of 5 stars$0.38+7.9%$12.00+3,038.1%-79.4%$8.57MN/A-0.353News CoverageKPRXKiora Pharmaceuticals3.9008 of 5 stars$2.76+3.8%$10.00+262.3%-38.8%$8.28M$16M2.6510Short Interest ↓CHROChromocell TherapeuticsN/A$1.35+3.8%N/A-7.5%$8.24MN/A-0.924News CoverageGap UpPMCBPharmaCyte Biotech2.3922 of 5 stars$1.20-2.4%N/A-44.1%$8.24MN/A2.264Short Interest ↓Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst Forecast Related Companies and Tools Related Companies GELS Competitors NXTC Competitors TSBX Competitors APRE Competitors CARM Competitors ACXP Competitors KPRX Competitors CHRO Competitors PMCB Competitors OBSV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLMD) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLMD Stock Free GLMD Stock Alerts